Harry Lamble is the founder of Sense Biodetection. Sense Biodetection has raised $79M in total funding. Latest round: Series B.
Harry Lamble is the founder of Sense Biodetection, a UK-based molecular diagnostics company established in 2014. Under his leadership, the company developed instrument-free, point-of-care diagnostic tests and secured multiple funding rounds, including a $50 million Series B in 2021. Sense Biodetection was acquired by Sherlock Biosciences in February 2023.
Full founder directory · Investor directory · Company funding database · Fundraising library